2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Okubo, K. Articles by Mochizuki, S. Search for Related Content PubMed PubMed Citation Articles by Okubo, K. Articles by Mochizuki, S.

Abnormal HDL Apolipoprotein A-I and A-II Kinetics in Hemodialysis Patients: A Stable Isotope Study

Keiko Okubo^*, Katsunori Ikewaki, Soichi Sakai, Norio Tada, Yoshindo Kawaguchi^* and Seibu Mochizuki

Divisions of *Nephrology and Hypertension Cardiology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan; Hibiya Ishikawa Kidney Center, Tokyo, Japan; and Department of General Medicine, Kashiwa Hospital, Jikei University School of Medicine, Chiba, Japan

Correspondence to Dr. Katsunori Ikewaki, Division of Cardiology, Department of Internal Medicine, Jikei University School of Medicine 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo, Japan 105-8461. Phone: 81-33433-1111; Fax: 81-33459-6043; E-mail: kikewaki{at}jikei.ac.jp

ABSTRACT. Low levels of HDL cholesterol and its major apoprotein constituents apoA-I and apoA-II are common in patients who have ESRD and are undergoing hemodialysis (HD), but the metabolic basis for the low HDL is poorly understood. This study aimed to investigate in vivo metabolism of apoA-I and apoA-II in five normotriglyceridemic ESRD-HD patients and compared it with five control subjects using endogenous stable isotope labeling methods coupled with a multicompartmental modeling. HDL cholesterol, apoA-I, and apoA-II levels were markedly decreased in the ESRD-HD patients by 39, 30, and 44%, respectively, in comparison with the control subjects. Fractional catabolic rate of apoA-I was found to be significantly increased by 59% to 0.360 ± 0.084/d in ESRD-HD patients as compared with control subjects of 0.227 ± 0.076/d (P = 0.028), whereas the production rates remained unchanged. Conversely, the apoA-II production rate significantly decreased by 31% to 1.50 ± 0.61 mg/kg per d in the ESRD-HD patients in comparison with control subjects of 2.17 ± 0.40 mg/kg per d (P = 0.047) with apoA-II fractional catabolic rate unchanged. These results revealed that the decreased levels of apoA-I are due solely to the increased rate of catabolism, whereas the reduced apoA-II levels are due primarily to the decreased rate of production in ESRD-HD patients. This differential regulation of apoA-I and apoA-II further supports the concept that apoA-I and apoA-II have distinct metabolic pathways.

This article has been cited by other articles:

				D. Muller, H. Mehling, B. Otto, R. Bergmann-Lips, F. Luft, J. Jordan, and R. Kettritz Niacin Lowers Serum Phosphate and Increases HDL Cholesterol in Dialysis Patients Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1249 - 1254. [Abstract] [Full Text] [PDF]

				J. S. Millar, C. Maugeais, K. Ikewaki, D. M. Kolansky, P.H. R. Barrett, E. C. Budreck, R. C. Boston, N. Tada, S. Mochizuki, J. C. Defesche, et al. Complete Deficiency of the Low-Density Lipoprotein Receptor Is Associated With Increased Apolipoprotein B-100 Production Arterioscler. Thromb. Vasc. Biol., March 1, 2005; 25(3): 560 - 565. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673